10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs

Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs

Anemia is a universal complication of advanced Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). It contributes substantially to cognitive impairment, chronic fatigue, decreased exercise tolerance, left ventricular hypertrophy (LVH), congestive heart failure, and cardiovascular mortality. The introduction of recombinant human erythropoietin and intravenous iron formulations transformed nephrology care by virtually eliminating reliance on chronic red blood cell transfusions and their associated complications (such as allosensitization, iron overload, and transfusion-transmitted infections).

---

Multifactorial Pathophysiology of CKD Anemia

The development of anemia in kidney disease results from a combination of primary endocrine failure, shortened erythrocyte survival, recurring blood losses, and disordered iron trafficking:

                     ┌────────────────────────────────────────────────────────┐
                     │          Mechanisms of Anemia in Kidney Disease        │
                     └────────────────────────────────────────────────────────┘
                                                  │
         ┌────────────────────────────────────────┼───────────────────────────────────────┐
         ▼                                        ▼                                       ▼
┌────────────────────────────────┐ ┌────────────────────────────────┐ ┌────────────────────────────────┐
│      Endocrine Deficiency      │ │  Uremic Toxins & Hemolysis     │ │ Disordered Iron Homeostasis    │
├────────────────────────────────┤ ├────────────────────────────────┤ ├────────────────────────────────┤
│ • Progressive loss of cortical │ │ • Erythrocyte lifespan reduced │ │ • High circulating hepcidin    │
│   peritubular interstitial     │ │   from 120 days to 60–90 days  │ │ • Internalization/degradation  │
│   fibroblasts                  │ │ • Oxidative membrane fragility │ │   of ferroportin iron channels │
│ • Insufficient erythropoietin  │ │ • Uremic marrow suppression    │ │ • Reticuloendothelial trapping │
│   (EPO) synthesis in response  │ │ • Annual dialytic blood loss   │ │ • Functional iron deficiency   │
│   to systemic tissue hypoxia   │ │   (1.5–3.0 L/year in HD lines) │ │ • Poor oral iron absorption    │
└────────────────────────────────┘ └────────────────────────────────┘ └────────────────────────────────┘

1. Deficient Endogenous Erythropoietin Production

The primary etiology of CKD anemia is the progressive loss of specialized peritubular interstitial capillary fibroblasts in the renal cortex. In healthy kidneys, these cells synthesize erythropoietin (EPO) in direct response to tissue hypoxia mediated by hypoxia-inducible factor transcription factors. As chronic glomerular and tubulointerstitial disease progresses to interstitial fibrosis, these fibroblasts differentiate into myofibroblasts, losing their endocrine capacity to transcribe and synthesize EPO.

2. Shortened Erythrocyte Survival & Dialytic Blood Losses

Normal circulating red blood cells have an average lifespan of 120 days. In advanced uremia, retention solutes, metabolic acidosis, and heightened oxidative stress damage erythrocyte membrane lipid bilayers and deformability, accelerating splenic and reticuloendothelial phagocytosis and reducing red blood cell survival to 60 to 90 days.

Furthermore, patients on maintenance hemodialysis experience obligate chronic blood loss averaging 1.5 to 3.0 liters of whole blood annually (~750 to 1,500 mg of elemental iron). Blood is lost through dialyzer membrane capillary trapping, residual blood retained in extracorporeal tubing sets, vascular access puncture site hematomas, and recurring diagnostic phlebotomy.

3. The Hepcidin-Ferroportin Axis & Disordered Iron Trafficking

Hepcidin, a 25-amino acid peptide hormone produced by hepatocytes, serves as the central master regulator of systemic iron homeostasis. Hepcidin transcription is stimulated by high systemic iron stores and, crucially, by proinflammatory cytokines (especially interleukin-6 [IL-6] via the JAK2/STAT3 signaling cascade).

In CKD, systemic low-grade chronic inflammation (uremia, dialysis membrane contact, vascular access infections) combined with diminished renal clearance causes circulating hepcidin levels to rise markedly. Hepcidin binds directly to ferroportin, the sole known cellular iron exporter present on duodenal enterocytes, splenic and hepatic reticuloendothelial macrophages, and hepatocytes. Binding triggers ferroportin endocytosis and lysosomal degradation, producing two pathological consequences:

1. Blockade of Intestinal Iron Absorption: Dietary iron taken up by enterocytes cannot be transferred to circulating transferrin and is lost when enterocytes desquamate.
2. Reticuloendothelial Iron Sequestration: Iron scavenged from senescent red blood cells by macrophages remains locked within intracellular storage pools and cannot be released to transferrin for delivery to erythroid precursors in the bone marrow. This state is termed functional iron deficiency.

---

Diagnostic Iron Surveillance & Differential Diagnosis

Accurate anemia management depends on distinguishing between absolute iron deficiency, functional iron deficiency, and anemia of chronic inflammation:

Absolute vs. Functional Iron Deficiency

• Absolute Iron Deficiency: Exhaustion of total body iron stores. Characterized by TSAT <20% and serum ferritin <100 ng/mL in non-dialysis CKD, or <200 ng/mL in maintenance hemodialysis. Results from chronic blood loss, poor nutritional intake, or prior untreated ESA therapy.
• Functional Iron Deficiency (Iron Sequestration / Block): Adequate or high total body iron stores that cannot be mobilized rapidly enough to meet the demand of accelerated erythropoiesis driven by ESAs. Characterized by TSAT <20% alongside normal or elevated serum ferritin (200 to 500+ ng/mL). Driven by high hepcidin levels secondary to chronic inflammation.

---

Target Parameters & The Landmark Clinical Trials

Historical nephrology practice attempted to normalize hemoglobin concentrations to healthy physiological baselines (>13.0 g/dL) using aggressive doses of erythropoiesis-stimulating agents. However, three landmark randomized controlled trials revealed serious cardiovascular toxicities associated with complete anemia correction:

                                    Landmark Trials in Anemia Correction
                                    
  CHOIR (2006)                       CREATE (2006)                      TREAT (2009)
  • 1,432 CKD Patients               • 603 CKD Patients                 • 4,038 Diabetic CKD Patients
  • Epoetin alfa: 13.5 vs 11.3 g/dL  • Epoetin beta: 13.0–15.0 g/dL     • Darbepoetin alfa: 13.0 vs Rescue
  • Higher target: 34% increase in   • Complete normalization failed    • Higher target: DOUBLED STROKE
    composite death, MI, and CHF       to reduce cardiovascular events    RISK (HR 1.92, p < 0.001)
    hospitalizations (HR 1.34)         and accelerated dialysis start     without reducing death/ESRD

Current KDIGO Hemoglobin Guidance & the FDA Boxed Warning

In response to these trials, guidelines and FDA labeling set safety boundaries:

1. ESA initiation (KDIGO 2026): in CKD G5D, suggest starting an ESA when hemoglobin is 9.0–10.0 g/dL or lower (2D); in non-dialysis CKD, including transplant recipients, individualize the starting point based on symptoms and the risks of transfusion versus ESA therapy.
2. ESA maintenance (KDIGO 2026): in adults, target hemoglobin below 11.5 g/dL (1D), individualized for quality of life and transfusion avoidance.
3. FDA boxed warning: ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis and tumor progression. In CKD trials, targeting hemoglobin above 11 g/dL raised these risks, and no target has been shown to be free of them, so labeling advises using the lowest dose sufficient to reduce transfusions.
4. First-line agent (KDIGO 2026): use an ESA rather than a HIF-PH inhibitor as first-line therapy once correctable causes are addressed (2D).

---

Iron Repletion Modalities & Protocols

                           Iron Repletion Hierarchy in Kidney Disease
                           
      Non-Dialysis CKD & Peritoneal Dialysis               Maintenance Hemodialysis (HD)
      ┌────────────────────────────────────┐              ┌─────────────────────────────┐
      │ Trial of Oral Iron (1–3 Months)    │              │ First-Line Intravenous Iron │
      │ • Ferrous sulfate / gluconate      │              │ • Iron sucrose (Venofer)    │
      │ • Low absorption due to hepcidin   │              │ • Sodium ferric gluconate   │
      │ • Frequent GI intolerance          │              │ • Ferric carboxymaltose     │
      └────────────────────────────────────┘              └─────────────────────────────┘
                        │                                                │
                        ▼ If Intolerant or Unresponsive                  ▼ Administration Protocols
      ┌────────────────────────────────────┐              ┌─────────────────────────────┐
      │ Intravenous (IV) Iron Therapy      │              │ Loading: 1,000 mg over sequential HD
      │ • Infusions at clinic or center    │              │ Maint: 25–100 mg weekly     │
      └────────────────────────────────────┘              └─────────────────────────────┘

1. Oral Iron Therapy Limitations

Oral iron preparations (such as ferrous sulfate 325 mg [65 mg elemental iron], ferrous gluconate, and polysaccharide iron complex) provide poor efficacy in advanced CKD and maintenance hemodialysis. Elevated circulating hepcidin degrades enterocyte ferroportin, limiting duodenal absorption to <5% of ingested doses. Furthermore, unabsorbed iron causes severe gastrointestinal toxicity in up to 50% of patients (nausea, constipation, epigastric cramping, and dark stools, which can obscure gastrointestinal bleeding). In hemodialysis, ongoing dialytic blood loss outpaces intestinal absorption capacity, making oral iron ineffective for maintaining iron balance.

2. Intravenous Iron Formulations & Protocols

Intravenous iron bypasses the duodenal absorption barrier and is delivered directly to reticuloendothelial macrophages, which process the carbohydrate-iron core and release iron to transferrin:

• Iron Sucrose (Venofer): Complex of polynuclear iron(III)-hydroxide in sucrose. Standard HD dose: 100 mg IV push into the venous line during dialysis over 2 to 5 minutes, or 200 mg over 10 minutes.
• Sodium Ferric Gluconate Complex (Ferrlecit): Iron macromolecule complexed with gluconate. Standard HD dose: 125 mg IV infusion over 10 minutes.
• Ferric Carboxymaltose (Injectafer): Non-dextran iron carbohydrate complex enabling rapid, high-dose administration (e.g., 750 mg or 1,000 mg infused over 15 minutes), commonly utilized in non-dialysis CKD and peritoneal dialysis.
• Ferumoxytol (Feraheme): Superparamagnetic iron oxide nanoparticle; dosed at 510 mg IV over 15 minutes, repeated in 3 to 8 days.

Repletion Strategies in Maintenance Hemodialysis

• Loading Dose Protocol: Administering a cumulative total of 1,000 mg of elemental iron over consecutive hemodialysis sessions (e.g., 100 mg IV push per treatment for 10 consecutive sessions, or 125 mg for 8 sessions) when iron therapy is indicated (KDIGO 2026: ferritin ≤500 ng/mL and TSAT ≤30% in hemodialysis).
• Maintenance Dose Protocol: Small, periodic doses (e.g., 25 to 100 mg weekly or biweekly) to replace ongoing dialytic blood loss and prevent iron store depletion. KDIGO 2026 favors a proactive IV approach in HD; the PIVOTAL trial used up to 400 mg of iron sucrose monthly unless ferritin exceeded 700 ng/mL or TSAT reached 40%.
• Upper Safety Ceiling Thresholds: Withhold intravenous iron therapy if:
  • Serum ferritin exceeds 700 ng/mL (KDIGO 2026 practice point).
  • Transferrin saturation is 40% or higher.
  • Active systemic bacteremia or acute febrile infection is present (free iron accelerates bacterial virulence and biofilm formation).

---

Erythropoiesis-Stimulating Agents (ESAs)

ESAs are recombinant proteins that bind to and activate the erythropoietin receptor on bone marrow erythroid progenitor cells, stimulating proliferation, differentiation, and preventing erythroblast apoptosis.

1. Pharmacologic Classification of ESAs

• Short-Acting ESAs — Epoetin alfa (Epogen, Procrit): Recombinant human erythropoietin identical in amino acid sequence to endogenous EPO. Half-life is approximately 8 hours when administered IV and 24 hours subcutaneously. Typically dosed 50 to 100 units/kg IV three times weekly in hemodialysis, or subcutaneously once weekly in non-dialysis CKD.
• Long-Acting ESAs — Darbepoetin alfa (Aranesp): Hyperglycosylated erythropoietin analog with two additional N-linked carbohydrate chains (5 N-glycan chains vs. 3 in epoetin). Has lower receptor affinity but a 3-fold longer terminal half-life (~25 hours IV, ~48 hours SQ). Dosed every 1 to 2 weeks.
• Continuous Erythropoietin Receptor Activator (CERA) — Methoxy polyethylene glycol-epoetin beta (Mircera): Epoetin beta integrated with a single large linear 30 kDa methoxy polyethylene glycol polymer. Characterized by slow association and rapid dissociation with the EPO receptor, extending half-life to ~130 hours. Dosed every 2 to 4 weeks.

2. ESA Hyporesponsiveness / Resistance

ESA hyporesponsiveness is clinically defined as the failure to achieve or maintain target hemoglobin levels despite escalating doses (e.g., epoetin alfa >300 units/kg/week or darbepoetin alfa >1.5 mcg/kg/week), or the requirement for repeated dose increases to maintain stability. The systematic clinical evaluation of ESA resistance must follow a structured diagnostic hierarchy:

                    Systematic Evaluation of ESA Hyporesponsiveness
                                          │
    ┌─────────────────────────────────────┼─────────────────────────────────────┐
    ▼                                     ▼                                     ▼
1. Iron Deficiency (Most Common)       2. Systemic Inflammation             3. Dialysis Underdelivery
   • Absolute (Ferritin <200, TSAT <20%)  • Elevated hs-CRP, ESR              • spKt/V <1.2, URR <65%
   • Functional (Ferritin >200, TSAT <20%)• Vascular access infection         • Uremic marrow suppression
   • Occult GI blood loss                 • Occult abscess, periodontitis     • Inadequate dialyzer surface
                                          │
    ┌─────────────────────────────────────┼─────────────────────────────────────┐
    ▼                                     ▼                                     ▼
4. Hyperparathyroidism                 5. Nutritional Deficiencies          6. Rare Hematologic Disorders
   • Intact PTH >1,000 pg/mL              • Folate or Vitamin B12 deficiency   • Pure Red Cell Aplasia (PRCA)
   • Osteitis fibrosa cystica             • Protein-Energy Wasting (PEW)         (Anti-erythropoietin antibodies)
   • Marrow replacement with fibrosis    • Severe ascorbic acid deficiency    • Aluminum toxicity, hemoglobinopathy

---

Novel Oral Therapies: HIF-PH Inhibitors

Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) Inhibitors are oral agents that stimulate endogenous erythropoiesis. In the United States, daprodustat (Jesduvroq, approved 2023) and vadadustat (Vafseo, approved March 2024) are approved only for adults with anemia of CKD on dialysis (for at least 4 and 3 months, respectively). Both carry a boxed warning for death, myocardial infarction, stroke, venous thromboembolism and vascular access thrombosis, and vadadustat has been paid through the ESRD PPS transitional drug add-on since 2025.

Molecular Mechanism of Action

In normal oxygenated conditions (normoxia), prolyl hydroxylase domain (PHD) enzymes hydroxylate specific proline residues on the HIF-α transcription factor subunit. This hydroxylation targets HIF-α for polyubiquitination by the von Hippel-Lindau (VHL) tumor suppressor E3 ligase, directing it to the 26S proteasome for degradation.

HIF-PH inhibitors reversibly inhibit PHD enzymes, mimicking cellular hypoxia. Non-hydroxylated HIF-α stabilizes, accumulates in the cytoplasm, and translocates into the nucleus, where it dimerizes with HIF-β. The heterodimer binds to Hypoxia Response Elements (HREs) in target genes to coordinate a comprehensive erythropoietic response:

1. Stimulates Endogenous EPO Transcription: Triggers physiological EPO synthesis in both surviving renal cortical fibroblasts and secondary hepatic sites.
2. Suppresses Hepcidin Transcription: Directly downregulates hepatic hepcidin production, restoring ferroportin expression on enterocytes and macrophages.
3. Enhances Iron Mobilization: Upregulates duodenal ferric reductase (Dcytb), divalent metal transporter 1 (DMT1), transferrin, and transferrin receptor-1, improving dietary iron absorption and mobilizing stored iron into functional erythropoiesis.

Despite the oral route and near-physiologic EPO levels, KDIGO 2026 suggests an ESA rather than a HIF-PH inhibitor as first-line therapy (2D) and advises avoiding HIF-PH inhibitors in people with prior cardiovascular or thrombotic events, active cancer, polycystic kidney disease or proliferative retinopathy. Use the same hemoglobin thresholds as for ESAs, and do not combine the two drug classes.